Cutaneous Melanoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
No BRAF exon 11 mutations were observed among seven CMs and nine UMs that were wild-type for exon 15.
|
14522897 |
2003 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations have recently been detected with a high frequency (66%) in cutaneous melanoma.
|
14501284 |
2003 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to determine whether the T1799A BRAF mutation found in cutaneous melanoma is also present in conjunctival melanoma.
|
15277467 |
2004 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
An activating mutation has been recently observed in cutaneous melanoma in a downstream component of RAS-BRAF.
|
15179189 |
2004 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Significant differences in BRAF exon 15 mutation frequency were found: 14/16 (87.5%) in common acquired naevi (CANs), 9/12 (75%) in CMs, 0/26 in Spitz naevi and 3/25 (12%) in blue naevi (p < 0.01).
|
15252839 |
2004 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that UV exposure, plays a role in the genesis of BRAF mutations in cutaneous melanoma, despite the absence of the characteristic C>T or CC>TT mutation signature associated with UV exposure, and suggests mechanisms other than pyrimidine dimer formation are important in UV-induced mutagenesis.
|
15060100 |
2004 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
With regard to the frequency of V599E BRAF mutations, AM significantly differs from CM (P < or = .0001), which suggests that BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.
|
15578519 |
2004 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recently, a high incidence of activating mutations in the kinase domain of the BRAF gene has been reported in malignant melanoma of the skin.
|
15588860 |
2005 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In contrast to cutaneous melanoma, there is no evidence that BRAF mutations are involved in the activation of the mitogen-activated protein kinase (MAPK) pathway in uveal melanoma, although there is increasing evidence that this pathway is activated frequently in the latter tumours.
|
15928660 |
2005 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have shown frequent mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) or NRAS (neuroblastoma RAS viral [V-ras] oncogene homolog) genes in cutaneous melanoma, but the relationship between these alterations and tumor cell proliferation has not been examined in human melanoma.
|
16098042 |
2005 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Absence of BRAF gene mutation in non-melanoma skin tumors.
|
16687919 |
2006 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent molecular studies have identified recurrent BRAF mutations in both cutaneous melanoma and thyroid malignancies.
|
16049985 |
2006 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Thus far, there is very limited data combining BRAF and NRAS mutation analysis to explore differences between cutaneous melanoma subtypes.
|
16899595 |
2006 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic B-RAF gene mutation has been identified in many malignancies and detected at a high frequency in cutaneous malignant melanoma.
|
17404088 |
2007 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
|
19383313 |
2008 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
|
18227705 |
2008 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A set of 250 probes representing 209 genes that were significantly (raw P< or =0.001) associated with BRAF mutation status was identified and 17 of these were previously shown to be implicated in cutaneous melanoma progression or pigmentation pathway-associated genes driven by the microphthalmia transcription factor (MITF).
|
19383316 |
2008 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, germline variants of the melanocortin-1 receptor (MC1R) have been shown to be associated with an increased risk for BRAF mutant but not BRAF wild-type cutaneous melanoma.
|
19493000 |
2009 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutational activation of the BRAF oncogene is the most common genetic alteration in cutaneous melanoma.
|
19033861 |
2009 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.
|
19037234 |
2009 |
Cutaneous Melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The BRAF/NRAS mutation status and expression of COX-2 and iNOS were examined to compare their prognostic value for overall survival (OS) in stage III malignant cutaneous melanoma.
|
19039588 |
2009 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We propose an assay based on the use of a locked nucleic acid probe and an allele specific primer to measure plasma-circulating BRAF(V600E) concentration in patients affected by cutaneous melanoma (n=55) and non-melanoma skin cancers (n=13) as well as 18 healthy subjects.
|
20576522 |
2010 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.
|
19571821 |
2010 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site.
|
21324100 |
2011 |